Collagen - A necessary accomplice in the metastatic process

Cancer Genomics and Proteomics

Volumn 4, Issue 5, 2007, Pages 319-328

  Nerenberg, Paul S ^a   Salsas Escat, Ramon ^a   Stultz, Collin M ^a  

^a Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

Cancer; Collagen; Collagenolysis; Metastasis; MMPs; Review

Indexed keywords

COLLAGEN; D 93 ANTIBODY; GELATINASE A; HUIV 26; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

BASEMENT MEMBRANE; CANCER PATIENT; COLLAGEN DEGRADATION; ENZYME INHIBITION; EXTRACELLULAR MATRIX; GENETIC TRANSCRIPTION; HUMAN; HYPOTHESIS; IMMUNE RESPONSE; MEDICAL RESEARCH; METASTASIS; NONHUMAN; PROGNOSIS; PROTEIN FUNCTION; REVIEW; TUMOR CELL;

EID: 35948949062     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. American Cancer Society Facts and Figures 2006.
2. Sporn MB: The war on cancer: a review. Ann NY Acad Sci 833: 137-146, 1997.
3. Sporn MB: The war on cancer. Lancet 347: 1377-1381, 1996.
4. Greenlee RT et al: Cancer statistics, 2001. CA Cancer J Clin 51: 15-36, 2001.
5. Kumar V, Cotran RS and Robbins SL: Neoplasia. In: Basic Pathology. Philadelphia, Saunders, pp. 165-210, 2003.
6. Ray JM and Stetler-Stevenson WG: The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J 7: 2062-2072, 1994.
7. Chambers AF and Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89: 1260-1270, 1997.
8. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
9. Folkman J and Klagsbrun M: Angiogenic factors. Science 235: 442-447, 1987.
10. Lijnen HR et al: Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry 37: 4699-4702, 1998.
11. Patterson BC and Sang QA: Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem 272: 28823-28825, 1997.
12. Li G and Herlyn M: Dynamics of intercellular communication during melanoma development. Mol Med Today 6: 163-169, 2000.
13. Beavon IR: The E-cadherin-catenin complex in tumour metastasis: structure, function and regulation. Eur J Cancer 36: 1607-1620, 2000.
14. Kalluri R: Basement membranes: structure, assembly, and role in tumour angiogenesis. Nat Rev Cancer 3: 422-433, 2003.
15. Hotary K et al: A cancer cell metalloprotease triad regulates the basement membrane transmigration program. Genes Dev 20: 2673-2686, 2006.
16. Liotta LA et al: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67-69, 1980.
17. Salo T, Liotta LA and Tryggvason K: Purification and characterization of a murine basement membrane collagen-degrading enzyme secreted by metastatic tumor cells. J Biol Chem 258: 3058-3063, 1983.
18. Albini A et al: Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst 83: 775-779, 1991.
19. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002.
20. Woodhouse EC, Chuaqui RF and Liotta LA: General mechanisms of metastasis. Cancer 80: 1529-1537, 1997.
21. Roos E and Dingemans KP: Mechanisms of metastasis. Biochim Biophys Acta 560: 135-166, 1979.
22. Orr FW, Wang HH, Lafrenie RM, Scherbarth S and Nance DM: Interactions between cancer cells and the endothelium in metastasis. J Pathol 190: 310-329, 2000.
23. Liotta LA, Kleinerman J and Saidel GM: Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 34: 997-1003, 1974.
24. Fidler IJ: The relationship of embolic homogeneity, number, size and viability to the incidence of experimental metastasis. Eur J Cancer 9: 223-227, 1973.
25. Morris VL et al: Early interactions of cancer cells with the microvasculature in mouse liver and muscle during hematogenous metastasis: videomicroscopic analysis. Clin Exp Metastasis 11: 377-390, 1993.
26. Koop S et al: Fate of melanoma cells entering the microcirculation: over 80% survive and extravasate. Cancer Res 55: 2520-2523, 1995.
27. Maniotis AJ et al: Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 155: 739-752, 1999.
28. Stryer L: Biochemistry. New York, W.H. Freeman and Company, 1089 p, 1988.
29. Rich A and Crick FHC: The molecular structure of collagen. J Mol Biol 3: 482-506, 1961.
30. Brodsky B and Ramshaw JAM: The Collagen Triple-Helix Structure. Matrix Biology 15: 545-554, 1997.
31. Bella J, Brodsky B and Verman HM: Crystal and molecular structure of a collagen like peptide at 1.9 Å resolution. Science 266: 75-81, 1994.
32. Shah NK, Ramshaw JAM, Kirkpatrick A, Shah C and Brodsky B: A host-guest set of triple helical peptides: Stability of Gly-X-Y triplets containing common non-polar residues. Biochemistry 35: 5510-5517, 1996.
33. Kramer RZ, Bella J, Mayville P, Brodsky B and Berman HM: Sequence dependent conformational variations of collagen triple-helical structure. Nat Struct Biol 6: 454-457, 2001.
34. Kramer RZ, Bella J and Brodsky B: The crystal structure of a collagen-like peptide with a biologically relevant sequence. J Mol Biol 311: 131-147, 2001.
35. Persikov AV, Ramshaw JAM and Brodsky B: Prediction of Collagen Stability from Amino Acid Sequence. J Biol Chem 280: 19343-19349, 2005.
36. Li MH, Fan P, Brodsky B and Baum J: Two-dimensional NMR assignments and conformation of (Pro-Hyp-Gly)10 and a designed collagen triple-helical peptide. Biochemistry 32: 7377-7387, 1993.
37. Persikov AV, Xu Y and Brodsky B: Equilibrium thermal transitions of collagen model peptides. Protein Sci 13: 893-902, 2004.
38. Stultz CM: Localized Unfolding of Collagen Explains Collagenase Cleavage at Imino-Poor sites. J Mol Biol 319: 997-1003, 2002.
39. Stultz CM: The folding mechanism of collagen-like model peptides explored through detailed molecular simulations. Protein Sci 15: 2166-2177, 2006.
40. Jones CB, Sane DC and Herrington DM: Matrix metalloproteinases: A review of their structure and role in acute coronary syndrome. Cardiovasc Res 59: 812-823, 2003.
41. Chakraborti S, Mandal M, Das A, Mandal A and Chakraborti T: Regulation of matrix metalloproteinases: An overview. Mol Cell Biochem 253: 269-285, 2003.
42. Overall CM: Molecular determinants of metalloproteinase substrate specificity. Mol Biotechnol 22: 51-86, 2002.
43. Bode W et al: Structural properties of matrix metalloproteinases. Cell Mol Life Sci 55: 639-652, 1999.
44. Lauer-Fields JL, Juska D and Fields GB: Matrix metalloproteinases and collagen metabolism. Biopolymers 66: 19-32, 2002.
45. Maskos K: Crystal structures of MMPs in complex with physiological and pharmacological inhibitors. Biochimie 87: 249-263, 2005.
46. Fields GB: A Model for Interstitial Collagen Catabolism by Mammalian Collagenases. J Theor Biol 153: 585-602, 1991.
47. Postlethwaite AE and Kang AH: Collagen-and collagen peptide-induced Chemotaxis of human blood monocytes. J Exp Med 143: 1299-1307, 1976.
48. Normann SJ: Macrophage infiltration and tumor progression. Cancer Met Rev 4: 277-291, 1985.
49. Bingle L, Brown NJ and Lewis CE: The role of tumour-associated macrophages in tumor progression: implications for new anticancer therapies. J Pathol 196: 846-852, 2002.
50. Pollard JW: Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4: 71-78, 2004.
51. Menetrier-Caux C et al: Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 92: 4778-4791, 1998.
52. Carmeliet P and Jain RK: Angiogenesis in cancer and other diseases. Nature 407: 249-257, 2000.
53. Boudreau N and Myers C: Breast cancer-induced angiogenesis: multiple mechanisms and the role of the microenvironment. Breast Cancer Res 5: 140-146, 2003.
54. Voronov E et al: IL-1 is required for tumor invasiveness and angiogenesis. Proc Nat Acad Sci 100: 2645-2650, 2003.
55. Chirivi RG et al: IL-1α gene-transfected human melanoma cells increase tumor-cell adhesion to endothelial cells and their retention in the lung of nude mice. Int J Cancer 67: 856-863, 1996.
56. Vidal-Vanalocha F et al: Interleukin 1 (IL-1)-dependent melanoma hepatic metastasis in vivo; increased endothelial adherence by IL-1-induced mannose receptors and growth factor production in vitro. J Natl Cancer Inst 88: 198-205, 1996.
57. Ito A et al: Degradation of interleukin 1beta by matrix metalloproteinases. J Biol Chem 271: 14657-14660, 1996.
58. Parks WC, Wilson CL and Lopez-Boado YS: Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 4: 617-629, 2004.
59. Thomas AH, Edelman ER and Stultz CM: Collagen fragments modulate innate immunity. Exp Biol Med 232: 406-411, 2007.
60. Xu J et al: Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol 154: 1069-1079, 2001.
61. Roth JM et al: Inhibition of experimental metastasis by targeting the HUIV26 cryptic epitope in collagen. Am J Pathol 168: 1576-1586, 2006.
62. Pernasetti F et al: Novel anti-denatured collagen humanized antibody D93 inhibits angiogenesis and tumor growth: An extracellular matrix-based therapeutic approach. Int J Oncol 29: 1371-1379, 2006.
63. Folgueras AR, Pendas AM, Sanchez LM and Lopez-Otin C: Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Bio 48: 411-424, 2004.
64. Westermarck J and Kahari VM: Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 13: 781-792, 1999.
65. Galvez BG, Matias-Roman S, Albar JP, Sanchez-Madrid F and Arroyo AG: Membrane type 1-matrix metalloproteinase is activated during migration of human endothelial cells and modulates endothelial motility and matrix remodelling. J Biol Chem 276: 37491-37500, 2001.
66. Melchiori A, Albini A, Ray JM and Stetler-Stevenson WG: Inhibition of tumor cell invasion by a highly conserved peptide sequence from the matrix metalloproteinase enzyme prosegment. Cancer Res 52: 2353-2356, 1992.
67. Fotouhi N et al: Potent peptide inhibitors of stromelysin based on the prodomain region of matrix metallproteinases. J Biol Chem 269: 30227-30231, 1994.
68. Lang R et al: Crystal structure of the catalytic domain of Mmp-16/Mt3-Mmp: characterization of Mt-Mmp specific features. J Mol Biol 336: 213-225, 2004.
69. Bode W and Maskos K: Structural basis of the matrix metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases. Biol Chem 384: 863-872, 2003.
70. Murphy G and Knauper V: Relating Matrix Metalloproteinase Structure to Function: Why the "hemopexin" domain? Matrix Biology 15: 511-518, 1997.
71. Long G, Braswell E, Zhu D, Baum J and Brodsky B: Characterization of collagen-like peptides containing interruptions in the repeating Gly-X-Y sequence. Biochemistry 32: 11688-11695, 1993.
72. Nerenberg PS, Salas-Escat R and Stultz CM: Do collagenases unwind triple-helical collagen prior to peptide bond hydrolysis? Reinterpreting experimental observations with mathematical models. Proteins in press, 2007.
73. Trikha M et al: Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 9: 4653-4665, 2003.
74. Jang H et al: Proceedings of ASCO Annual Meeting New Orleans, 2004.
75. Yan L, Anderson GM, DeWitte M and Nakada MT: Therapeutic potential of cytokine and chemokine antagonists in cancer therapy. Eur J Cancer 42: 793-802, 2006.
76. Yang XD, Corvalan JR, Wang P, Roy CM and Davis CG: Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states. J Leukoc Biol 66: 401-410, 1999.
77. Huang S et al: Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol 161: 125-134, 2002.